Retatrutide, a new dual agonist of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) target, is showing promising outcomes in preliminary clinical trials . Current research suggests https://webookmarks.com/story7009085/retatrutide-emerging-investigations-and-potential-therapeutic-uses